Emerson Process Management (St. Louis, MO) has been chosen to automate the first Chinese plant to produce monoclonal antibody drugs.
Emerson Process Management (St. Louis, MO) has been chosen to automate the first Chinese plant to produce monoclonal antibody drugs. The plant, owned by Shanghai CP Guojian Pharmaceutical Company and located in the Zhangjiang Hi-Tech Park in Shanghai, China, will have the largest mammalian cell-culture system in Asia. Monoclonal antibody drug production is expected to begin in August of this year.
The automation approach will include Emerson’s “PlantWeb” architecture with Foundation fieldbus instrumentation and the DeltaV digital automation system.
The Emerson solution is intended to meet the end-user's goal of applying advanced technology to all phases of pharmaceutical production while keeping costs low, meeting the construction schedule, and achieving a smooth start-up. Company officials expect to meet international standards with the products manufactured at this facility.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.